Latest News
Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
MDimune Signs Research Agreement with YiPSCELL to Develop iPSC-based BioDrone™ Therapeutics
Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
Sep 15, 2022 Caravan Biologix and MDimune announced their collaboration to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers.
MDimune is named as one of the Top 10 Biotech Startups in APAC - 2022
MDimune Signs Research Agreement with YiPSCELL to Develop iPSC-based BioDrone™ Therapeutics
Caravan Biologix, Inc. Collaborates with MDimune on Cell-Derived NanoVesicles for Cancer
May 2022 A distinguished panel and the editorial board of Life Science Review APAC selected a list of biotech startups, naming MDimune: The Pioneer of Cell-Derived-Vesicle Therapeutics
MDimune Signs Research Agreement with YiPSCELL to Develop iPSC-based BioDrone™ Therapeutics
MDimune Signs Research Agreement with YiPSCELL to Develop iPSC-based BioDrone™ Therapeutics
MDimune Signs Research Agreement with YiPSCELL to Develop iPSC-based BioDrone™ Therapeutics
Feb 28, 2022 MDimune announced the joint research agreement with YiPSCELL to develop Biodrone™ Platform therapeutics based on induced pluripotent stem cells (iPSCs).
About Us
BioDrone™ Platform Technology
BioDrone™ Platform Technology
BioDrone™ Platform Technology
Groundbreaking drug delivery platform that precisely delivers various drugs to targeted lesions by loading them into cell-derived vesicles (CDVs) derived from human cells.
Business Model
BioDrone™ Platform Technology
BioDrone™ Platform Technology
MDimune is currently seeking partners for R&D collaborations that utilize the BioDrone™ (CDVs) platform for next-generation cell therapies or targeted payload delivery.
Open Innovation
BioDrone™ Platform Technology
Open Innovation
Platform Inside Development Outside (PIDO) model to collaborate with pharma/biotech partners in diverse therapeutic areas (cancer, rare diseases, CNS disorders, etc.).